S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Coherus BioSciences Stock Forecast, Price & News

+0.59 (+8.15%)
(As of 07/1/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
826,628 shs
Average Volume
965,461 shs
Market Capitalization
$606.22 million
P/E Ratio
Dividend Yield
Price Target

Coherus BioSciences Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.60 Rating Score
142.7% Upside
$19.00 Price Target
Short Interest
13.44% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.74mentions of Coherus BioSciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($3.77) to ($1.87) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.24 out of 5 stars

Medical Sector

330th out of 1,428 stocks

Biological Products, Except Diagnostic Industry

52nd out of 217 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Coherus BioSciences logo

About Coherus BioSciences (NASDAQ:CHRS)

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

CHRS Stock News Headlines

Coherus BioSciences (NASDAQ:CHRS) Now Covered by UBS Group
Coherus: Will Its Chinese Gambit Fail?
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
$-287.10 million
Pretax Margin


Sales & Book Value

Annual Sales
$326.55 million
Book Value
$1.27 per share


Free Float
Market Cap
$606.22 million

Social Links

Coherus BioSciences Frequently Asked Questions

Should I buy or sell Coherus BioSciences stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Coherus BioSciences stock.
View analyst ratings for Coherus BioSciences
or view top-rated stocks.

What is Coherus BioSciences' stock price forecast for 2022?

5 equities research analysts have issued 12 month price targets for Coherus BioSciences' stock. Their CHRS stock forecasts range from $7.00 to $30.00. On average, they anticipate Coherus BioSciences' share price to reach $19.00 in the next twelve months. This suggests a possible upside of 142.7% from the stock's current price.
View analysts' price targets for Coherus BioSciences
or view top-rated stocks among Wall Street analysts.

How has Coherus BioSciences' stock performed in 2022?

Coherus BioSciences' stock was trading at $15.96 on January 1st, 2022. Since then, CHRS stock has decreased by 50.9% and is now trading at $7.83.
View the best growth stocks for 2022 here

When is Coherus BioSciences' next earnings date?

Coherus BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Coherus BioSciences

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) issued its earnings results on Thursday, May, 5th. The biotechnology company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.80) by $0.44. The biotechnology company had revenue of $60.12 million for the quarter, compared to the consensus estimate of $68.07 million. Coherus BioSciences had a negative trailing twelve-month return on equity of 211.68% and a negative net margin of 69.24%.
View Coherus BioSciences' earnings history

Who are Coherus BioSciences' key executives?

Coherus BioSciences' management team includes the following people:
  • Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 67, Pay $1.86M) (LinkedIn Profile)
  • Mr. McDavid Stilwell, Chief Financial Officer (Age 50, Pay $756k) (LinkedIn Profile)
  • Mr. Vladimir Vexler Ph.D., Chief Scientific Officer (Age 64, Pay $778.28k) (LinkedIn Profile)
  • Mr. Richard L. Hameister, Chief Technical Officer
  • Mr. Thomas F. Fitzpatrick, Chief Legal Officer
  • Cheston Turbyfill, VP of Communications
  • Mr. Chris Thompson, Exec. VP of Sales
  • Ms. Rebecca Sunshine, Exec. VP of HR (Age 59)
  • Mr. Michael A. Fleming, Chief Strategy Officer
  • Mr. Michael Chen, Sr. VP of Commercial Analytics & Trade

What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?

21 employees have rated Coherus BioSciences CEO Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among Coherus BioSciences' employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Coherus BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

What is Coherus BioSciences' stock symbol?

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

How do I buy shares of Coherus BioSciences?

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Coherus BioSciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $7.83.

How much money does Coherus BioSciences make?

Coherus BioSciences (NASDAQ:CHRS) has a market capitalization of $606.22 million and generates $326.55 million in revenue each year. The biotechnology company earns $-287.10 million in net income (profit) each year or ($2.730010) on an earnings per share basis.

How many employees does Coherus BioSciences have?

Coherus BioSciences employs 332 workers across the globe.

Does Coherus BioSciences have any subsidiaries?

The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..
Read More

When was Coherus BioSciences founded?

Coherus BioSciences was founded in 2010.

How can I contact Coherus BioSciences?

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The official website for Coherus BioSciences is www.coherus.com. The biotechnology company can be reached via phone at (650) 649-3530 or via email at darrington@coherus.com.

This page (NASDAQ:CHRS) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.